QualityStocks would like to highlight International Stem Cell Corporation (http://www.qualitystocks.net/stocks1.html">OTCBB: ISCO), focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs).
In the company’s news yesterday,
International Stem Cell Corp. reported positive 12-week results from its pre-clinical in vivo Parkinson’s disease study. This behavioral study’s primary objective was to demonstrate the therapeutic benefits of neuronal cells derived from a human parthenogenetic stem cell line in a rat model of Parkinson’s disease (PD).
A common neurodegenerative disorder caused by a progressive degeneration of dopamine-producing neurons resulting in gradual dysfunction of the motor system, PD can eventually lead to death. Pharmacological treatments can be useful in the early stages of the disease, but the continuous use of pro-dopaminergic medication in time becomes ineffective and can even worsen some of the motor symptoms.
In contrast, ISCO’s proprietary technology is based on a homogeneous population of neuronal cells (NCs) derived from homozygous hpSCs through a scalable and efficient method. These parthenogenetically derived NCs are cryopreservable and can become neurons once they are implanted into the brain. They hold tremendous therapeutic potential not only because they can differentiate into dopamine-producing neurons, but also because they could provide a level of protection to existing neurons affected by the disease.
ISCO utilized a well-established and validated model of PD for its pre-clinical study. The experimental rats with unilateral dopamine (6-OHDA) lesions survived the inoculation of cells into the brain and signs of improvement in rotational behavior of these animals were obvious. Correlational analysis of rotation intensity confirmed a difference between the drug effects in the control group vs. experimental (transplanted) group of animals. Interim results demonstrate that just a single injection of hpSC-derived neuronal cells can lead to a notable slowdown in the progression of the disease.
“This is a very important result for our pre-clinical Parkinson’s program,” Dr. Ruslan Semechkin, Vice President – head of R&D, commented. “The initial in vivo results are very encouraging and show the therapeutic promise of hpSC-derived neuronal cells in the treatment of individuals with Parkinson’s disease. Results from this behavioral study will be presented and discussed together with the results of non-human primate study before the end of the first quarter of 2013.
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.